

Highlights of This Issue 717

EDITORIAL

- 719** Adaptive Resistance to Chemotherapy, A Multi-FAK-torial Linkage
Kristin N. Taylor and David D. Schlaepfer

REVIEW

- 724** Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers
Masanori Kawakami, Lisa Maria Mustachio, Xi Liu, and Ethan Dmitrovsky

SMALL MOLECULE THERAPEUTICS

- 732** JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-Small Cell Lung Cancers
Sean P. Pitroda, Melinda E. Stack, Gene-Fu Liu, Sui-Sui Song, Lucy Chen, Hua Liang, Akash D. Parekh, Xiaona Huang, Paul Roach, Mitchell C. Posner, Ralph R. Weichselbaum, and Nikolai N. Khodarev
- 740** Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer
Toshiyuki Hirano, Hiroyuki Yasuda, Junko Hamamoto, Shigenari Nukaga, Keita Masuzawa, Ichiro Kawada, Katsuhiko Naoki, Tatsuya Niimi, Shinya Mimasu, Hideki Sakagami, Kenzo Soejima, and Tomoko Betsuyaku
- 751** Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models
Jing Ai, Yi Chen, Xia Peng, Yinchun Ji, Yong Xi, Yanyan Shen, Xinying Yang, Yi Su, Yiming Sun, Yinglei Gao, Yuchi Ma, Bing Xiong, Jingkan Shen, Jian Ding, and Meiyu Geng
- 763** SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules
Fang Wang, Li Zheng, Yuyao Yi, Zhuang Yang, Qiang Qiu, Xiaoyan Wang, Wei Yan, Peng Bai, Jianhong Yang, Dan Li, Heying Pei, Ting Niu, Haoyu Ye, Chunlai Nie, Yiguo Hu, Shengyong Yang, Yuquan Wei, and Lijuan Chen

LARGE MOLECULE THERAPEUTICS

- 776** Relative Target Affinities of T-Cell-Dependent Bisppecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model
Danielle Mandikyan, Nene Takahashi, Amy A. Lo, Ji Li, Jeffrey Eastham-Anderson, Dionysos Slaga, Jason Ho, Maria Hristopoulos, Robyn Clark, Klara Totpal, Kedan Lin, Sean B. Joseph, Mark S. Dennis, Saileta Prabhu, Teemu T. Junttila, and C. Andrew Boswell
- 786** MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding *In Vivo* Activity against HER2-Expressing Tumors
Pablo Avilés, Juan Manuel Domínguez, María José Guillén, María José Muñoz-Alonso, Cristina Mateo, Raquel Rodríguez-Acebes, José Manuel Molina-Guijarro, Andrés Francesch, Juan Fernando Martínez-Leal, Simon Munt, Carlos M. Galmarini, and Carmen Cuevas
- 795** Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Andrew C. Phillips, Erwin R. Boghaert, Kedar S. Vaidya, Hugh D. Falls, Michael J. Mitten, Peter J. DeVries, Lorenzo Benatuil, Chung-Ming Hsieh, Jonathan A. Meulbroek, Sanjay C. Panchal, Fritz G. Buchanan, Kenneth R. Durbin, Martin J. Voorbach, David R. Reuter, Sarah R. Mudd, Lise I. Loberg, Sherry L. Ralston, Diana Cao, Hui K. Gan, Andrew M. Scott, and Edward B. Reilly

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

- 806** Wnt/ β -Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Guangming Chen, Chenxi Gao, Xuan Gao, Dennis Han Zhang, Shih-Fan Kuan, Timothy F. Burns, and Jing Hu
- 814** A Spatio-Temporal Model of Macrophage-Mediated Drug Resistance in Glioma Immunotherapy
Yongjiang Zheng, Jiguang Bao, Qiyi Zhao, Tianshou Zhou, and Xiaoqiang Sun

Table of Contents

- 825** Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer
Sung Baek Jeong, Ji Hye Im, Jeong-Hoon Yoon, Quyen Thu Bui, Sung Chul Lim, Joon Myong Song, Yumi Shim, Jieun Yun, Janghee Hong, and Keon Wook Kang

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 838** MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis
Hee Kyung Kim, InKyoung Lee, Heejin Bang, Hee Cheol Kim, Woo Yong Lee, Seong Hyeon Yun, Jeeyun Lee, Su Jin Lee, Young Suk Park, Kyoung-Mee Kim, and Won Ki Kang

- 849** PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
Diede Brunen, Romy C. de Vries, Cor Liefink, Roderick L. Beijersbergen, and René Bernards

MODELS AND TECHNOLOGIES

- 858** Characterizing the Potency and Impact of Carbon Ion Therapy in a Primary Mouse Model of Soft Tissue Sarcoma
Jeremy M. Brownstein, Amy J. Wisdom, Katherine D. Castle, Yvonne M. Mowery, Peter Guida, Chang-Lung Lee, Francesco Tommasino, Chiara La Tessa, Emanuele Scifoni, Junheng Gao, Lixia Luo, Lorraine Da Silva Campos, Yan Ma, Nerissa Williams, Sin-Ho Jung, Marco Durante, and David G. Kirsch
- 869** Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
Elizabeth A. Kuczynski, Janna Krueger, Annabelle Chow, Ping Xu, Shan Man, Yogi Sundaravadanam, Jessica K. Miller, Paul M. Krzyzanowski, and Robert S. Kerbel




AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

T cell-dependent bispecific antibodies (TDBs) form immunological synapses between cancer cells and T cells. Cancer cell killing occurs when TDB simultaneously binds a cancer cell surface antigen and T cell receptors, such as CD3. TDBs can be tracked *in vivo* using radioimmunoconjugates that elucidate distinct metabolic fates. Upon target binding, a fraction of the antibody-receptor complex is internalized and directed for lysosomal degradation. Catabolites of ^{125}I -labeled TDBs freely diffuse across the cellular membrane, likely followed by entry to systemic circulation and renal clearance. ^{125}I -labeled TDBs indicate the proportion of TDBs available to form cytolytic synapses. Illustration credit: Allison Bruce, Genentech.



Molecular Cancer Therapeutics

17 (4)

Mol Cancer Ther 2018;17:717-882.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/17/4>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/17/4>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.